SS18 and soft tissue sarcoma: These findings are in agreement with our previous study in synovial sarcoma, another fusion-driven soft tissue sarcoma, in which we demonstrated that SS18-SSX-mediated IGF-IR signaling acts as a critical upstream modulator of YAP1/TAZ via deregulation of the Hippo upstream effectors LATS1 and MOB1 [31].